GSA Grants Proscia Multiple Award Schedule

PHILADELPHIA–(BUSINESS WIRE)–Proscia┬«, a leader in digital and computational pathology solutions, today announced that it has been recognized by a US General Service Administration (GSA) Multiple Award Schedule (MAS). This five-year agreement provides government agencies streamlined access to the company’s Concentriq┬« platform, helping them accelerate the adoption of digital pathology. Concentriq is available under contract number 47QTCA22D0089.

Through the MAS program, GSA simplifies the purchasing process for government agencies, including federal, state, and local governments, by providing long-term contracts at pre-negotiated prices. The program also connects these companies with experienced, trusted vendors as it carefully evaluates vendors before awarding contracts.

“Proscia looks forward to helping government organizations accelerate the adoption of digital pathology through the GSA,” said David West, CEO. “We demonstrated that we helped the Joint Pathology Center completely transform its pathology practice and look forward to continuing to advance this initiative while expanding relationships with other federal agencies.”

The Joint Pathology Center (JPC), the U.S. government’s premier reference center for pathology, announced in October 2020 that it has selected Proscia’s Concentriq platform for a complete transformation of its pathology practice. At the heart of this initiative, JPC is digitizing the world’s largest human tissue archive on Proscia’s Concentriq for Research, sparking a new wave of biomedical research. JPC has also chosen the company’s Concentriq Dx solution* to digitize its routine pathology consultations and provide patients with accurate, timely diagnoses.

Proscia’s Concentriq, the technology underlying the Concentriq for Research and Concentriq Dx solutions, is a unique, secure image and data management platform. It combines comprehensive functions for viewing, managing and analyzing images with powerful AI applications and seamlessly integrates solutions from Proscia, Proscia’s customers and other third-party providers into routine practice.

*Concentriq Dx is CE marked for in vitro diagnostic use in Europe and available for primary diagnosis in the US during the COVID-19 public health emergency.

About proscia

Proscia is a software company accelerating the digital transformation of pathology to transform our understanding of diseases like cancer. The Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old research and diagnostic standard towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes and fulfill the promise of accurate care. Leading diagnostic laboratories and 10 of the top 20 pharmaceutical companies rely on Proscia software every day. Visit proscia.com for more information.

Leave a Comment